Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity

30 Dec 2021

Abstract excerpt

Enzalutamide, a second-generation antiandrogen, is commonly prescribed for the therapy of advanced prostate cancer, but enzalutamide-resistant, lethal, or incurable disease invariably develops. To understand the molecular mechanism(s) behind enzalutamide resistance, here, we comprehensively analyzed a range of prostate tumors and clinically relevant models by gene expression array, immunohistochemistry, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hippo pathway signaling and YAP/TAZ
Share to Prostate Cancer Treatment and Research
Share to Renal and related cancers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34973338
DOI: 10.1016/j.jbc.2021.101556

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticityPMID 34973338Read ↗

Tribbles 2 confers enzalutamide resistance in prostate cancer by promoting lineage plasticitySemantic proximity Read ↗

HF-125, a first-in-class computer-modeled novel inhibitor of Tribbles 2, for therapy of enzalutamide resistant, neuroendocrine prostate cancerSemantic proximity Read ↗

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancerSemantic proximity Read ↗

Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells <i>in vitro</i>Semantic proximity Read ↗

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate CancerSemantic proximity Read ↗

Androgen Deprivation Induces Transcriptional Reprogramming in Prostate Cancer Cells to Develop Stem Cell-Like CharacteristicsSemantic proximity Read ↗

Unlocking the Role of OCT4 in Cancer Lineage Plasticity: A Cross-Cancer Perspective with an Emphasis on Prostate CancerSemantic proximity Read ↗

ID2 Promotes Lineage Transition of Prostate Cancer through FGFR and JAK-STAT SignalingSemantic proximity Read ↗

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate CancerSemantic proximity Read ↗

Notch as a Driver of Lineage Plasticity and Therapeutic Target in Enzalutamide-Resistant Prostate CancerSemantic proximity Read ↗

Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer.Semantic proximity Read ↗

SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.